Trials / Conditions / Palmoplantar Pustulosis

Palmoplantar Pustulosis

19 registered clinical trials studyying Palmoplantar Pustulosis — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis NCT07219420	UCB Biopharma SRL	Phase 3
Recruiting	A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants Wit NCT07013201	LEO Pharma	Phase 2
Terminated	Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis NCT07000630	Peking University First Hospital	N/A
Completed	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin NCT07428915	AI Labs Group S.L	—
Recruiting	Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers NCT05994976	Innovaderm Research Inc.	—
Terminated	Deucravacitinib for the Treatment of Palmoplantar Pustulosis NCT05710185	Brigham and Women's Hospital	Phase 4
Completed	Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) NCT05174065	Amgen	Phase 3
Terminated	A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) NCT05194839	Aristea Therapeutics, Inc.	Phase 2
Completed	A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in NCT04459507	Janssen Pharmaceutical K.K.	—
Terminated	A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part NCT04493424	Boehringer Ingelheim	Phase 2
Completed	A Study of KHK4827 in Subjects With Palmoplantar Pustulosis NCT04061252	Kyowa Kirin Co., Ltd.	Phase 3
Completed	Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplant NCT03972280	CSL Behring	Phase 1
Completed	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis NCT03633396	Vanda Pharmaceuticals	Phase 2
Completed	A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) NCT03988335	Aristea Therapeutics, Inc.	Phase 2
Completed	Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) NCT04572997	Kristian Reich	Phase 2
Completed	An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis NCT02641730	Janssen Pharmaceutical K.K.	Phase 3
Completed	Anakinra for Inflammatory Pustular Skin Diseases NCT01794117	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2
Completed	Immune Signature of Palmoplantar Pustulosis NCT01780857	Baylor Research Institute	—
Unknown	Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence NCT04566471	Peking University Third Hospital	—